Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Macular Degeneration × aflibercept × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 24 Neoplasm Metastasis 14 Neoplasms 10 Rectal Neoplasms 8 Colorectal Cancer Metastatic 7 Colonic Neoplasms 6 Lymphoma, Non-Hodgkin 5 Uveal Melanoma 4 Sarcoma 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Ovarian Neoplasms 4 Melanoma 4 Lymphoma, Mantle-Cell 4 Lymphoma, Large-Cell, Immunoblastic 4 Lymphoma, Large B-Cell, Diffuse 4 Lymphoma, Follicular 4 Lymphoma, B-Cell, Marginal Zone 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Fallopian Tube Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Burkitt Lymphoma 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Urethral Neoplasms 3 Stomach Neoplasms 3 Prostatic Neoplasms 3 Lung Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Renal Cell 3 Carcinoma, Non-Small-Cell Lung 3

Interventions

salicylhydroxamic acid 1 brolucizumab 1 aflibercept 1 Triamcinolone Acetonide 1 Ranibizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡